Literature DB >> 18583352

Extension of the SAEM algorithm for nonlinear mixed models with 2 levels of random effects.

Xavière Panhard1, Adeline Samson.   

Abstract

This article focuses on parameter estimation of multilevel nonlinear mixed-effects models (MNLMEMs). These models are used to analyze data presenting multiple hierarchical levels of grouping (cluster data, clinical trials with several observation periods, ...). The variability of the individual parameters of the regression function is thus decomposed as a between-subject variability and higher levels of variability (e.g. within-subject variability). We propose maximum likelihood estimates of parameters of those MNLMEMs with 2 levels of random effects, using an extension of the stochastic approximation version of expectation-maximization (SAEM)-Monte Carlo Markov chain algorithm. The extended SAEM algorithm is split into an explicit direct expectation-maximization (EM) algorithm and a stochastic EM part. Compared to the original algorithm, additional sufficient statistics have to be approximated by relying on the conditional distribution of the second level of random effects. This estimation method is evaluated on pharmacokinetic crossover simulated trials, mimicking theophylline concentration data. Results obtained on those data sets with either the SAEM algorithm or the first-order conditional estimates (FOCE) algorithm (implemented in the nlme function of R software) are compared: biases and root mean square errors of almost all the SAEM estimates are smaller than the FOCE ones. Finally, we apply the extended SAEM algorithm to analyze the pharmacokinetic interaction of tenofovir on atazanavir, a novel protease inhibitor, from the Agence Nationale de Recherche sur le Sida 107-Puzzle 2 study. A significant decrease of the area under the curve of atazanavir is found in patients receiving both treatments.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18583352      PMCID: PMC2722900          DOI: 10.1093/biostatistics/kxn020

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  8 in total

1.  Nonlinear mixed effects models for repeated measures data.

Authors:  M L Lindstrom; D M Bates
Journal:  Biometrics       Date:  1990-09       Impact factor: 2.571

2.  Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacokinetic interaction and bioequivalence cross-over trials.

Authors:  Xavière Panhard; France Mentré
Journal:  Stat Med       Date:  2005-05-30       Impact factor: 2.373

3.  Impact of modelling intra-subject variability on tests based on non-linear mixed-effects models in cross-over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients.

Authors:  Xavière Panhard; Anne-Marie Taburet; Christophe Piketti; France Mentré
Journal:  Stat Med       Date:  2007-03-15       Impact factor: 2.373

4.  The importance of modeling interoccasion variability in population pharmacokinetic analyses.

Authors:  M O Karlsson; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1993-12

Review 5.  Estimating population kinetics.

Authors:  S L Beal; L B Sheiner
Journal:  Crit Rev Biomed Eng       Date:  1982

6.  The SAEM algorithm for group comparison tests in longitudinal data analysis based on non-linear mixed-effects model.

Authors:  Adeline Samson; Marc Lavielle; France Mentré
Journal:  Stat Med       Date:  2007-11-30       Impact factor: 2.373

7.  Multivariate multilevel nonlinear mixed effects models for timber yield predictions.

Authors:  Daniel B Hall; Michael Clutter
Journal:  Biometrics       Date:  2004-03       Impact factor: 2.571

8.  Genetic analysis of growth curves using the SAEM algorithm.

Authors:  Florence Jaffrézic; Cristian Meza; Marc Lavielle; Jean-Louis Foulley
Journal:  Genet Sel Evol       Date:  2006-11-28       Impact factor: 4.297

  8 in total
  6 in total

1.  Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.

Authors:  Julie Bertrand; Emmanuelle Comets; Céline M Laffont; Marylore Chenel; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-06-27       Impact factor: 2.745

2.  Bioequivalence tests based on individual estimates using non-compartmental or model-based analyses: evaluation of estimates of sample means and type I error for different designs.

Authors:  Anne Dubois; Sandro Gsteiger; Etienne Pigeolet; France Mentré
Journal:  Pharm Res       Date:  2009-10-30       Impact factor: 4.200

3.  Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers.

Authors:  Ali-Akbar Golabchifar; Saeed Rezaee; Nahid Mobarghei Dinan; Abbas Kebriaeezadeh; Mohammad-Reza Rouini
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-10       Impact factor: 2.441

4.  Population analysis of ethnicity and first-phase insulin release.

Authors:  Lanyi Xie; Robert P Hoffman; Peter Veng-Pedersen
Journal:  Diabetes Res Clin Pract       Date:  2010-05-31       Impact factor: 5.602

5.  Geostatistical estimation and prediction for censored responses.

Authors:  José A Ordoñez; Dipankar Bandyopadhyay; Victor H Lachos; Celso R B Cabral
Journal:  Spat Stat       Date:  2017-12-12

6.  The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects.

Authors:  Phylinda L S Chan; Philippe Jacqmin; Marc Lavielle; Lynn McFadyen; Barry Weatherley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-19       Impact factor: 2.745

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.